Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic Acid
2. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide
3. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate
4. 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide
5. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide
6. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide Dihydrochloride
7. Capmatinib Dihydrochloride
8. Capmatinib Dihydrochloride Monohydrate
9. Capmatinib Hydrochloride
10. Capmatinib Hydrochloride Anhydrous
11. Capmatinib Metabolite M13
12. Capmatinib Metabolite M18
13. Cmc-583
14. Cmc583
15. Cnj-294
16. Cnj294
17. Inc-280
18. Inc280
19. Incb-28060
20. Incb-28060 Free Base
21. Incb28060
22. Nvp-inc280
23. Nvp-inc280-nx
24. Tabrecta
1. 1029712-80-8
2. Incb28060
3. Inc280
4. Inc-280
5. Nvp-inc280-nx
6. Incb-28060
7. Nvp-inc280
8. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide
9. Tabrecta
10. Capmatinib (incb28060)
11. Capmatinib [usan]
12. Incb-28060 Free Base
13. Inc28060
14. 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
15. Ty34l4f9oz
16. Incb 28060
17. Benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-
18. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide
19. Benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-;benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-
20. Capmatinib [inn]
21. Unii-ty34l4f9oz
22. Benzamide Hcl
23. Benzamide, 2-fluoro-n-methyl-4-(7-(6-quinolinylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)-
24. Capmatinib [mi]
25. Capmatinib (usan/inn)
26. Capmatinib [usan:inn]
27. Capmatinib(incb28060)
28. Incb28060(capmatinib)
29. Nyp-inc280-nx
30. Capmatinib [who-dd]
31. Mls006010965
32. Gtpl7904
33. Schembl1426819
34. Chembl3188267
35. Dtxsid90145595
36. Ex-a446
37. Amy18553
38. Bcp23444
39. Bdbm50146167
40. Mfcd18633285
41. Nsc777878
42. Nsc800067
43. S2788
44. Zinc43195321
45. Akos025396439
46. Bcp9000785
47. Ccg-268791
48. Cs-1541
49. Db11791
50. Nsc-777878
51. Nsc-800067
52. Sb16608
53. Ncgc00346702-01
54. Ncgc00346702-02
55. Ncgc00346702-05
56. Ac-25890
57. As-74142
58. Da-33530
59. Hy-13404
60. Smr004702769
61. Ft-0746310
62. D10696
63. J-509516
64. Q27075685
65. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2- Yl)benzamide
66. 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
67. 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazolo[1,2-b][1,2,4]triazin-2-yl]benzamide
68. 2-fluoro-n-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide
Molecular Weight | 412.4 g/mol |
---|---|
Molecular Formula | C23H17FN6O |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 412.14478735 g/mol |
Monoisotopic Mass | 412.14478735 g/mol |
Topological Polar Surface Area | 85.1 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 637 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
FDA Label
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure - patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.
L01EX17
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX - Other protein kinase inhibitors
L01EX17 - Capmatinib
Absorption
The oral bioavailability of capmatinib is estimated to be >70%. Following oral administration, maximum plasma concentrations are achieved within 1 to 2 hours (Tmax). Co-administration with a high-fat meal increased capmatinib AUC by 46% with no change in Cmax (as compared to fasted conditions), and co-administration with a low-fat meal had no clinically meaningful effects on exposure.
Route of Elimination
Following oral administration of radiolabeled capmatinib, approximately 78% of the radioactivity is recovered in feces, of which ~42% is unchanged parent drug, and 22% is recovered in the urine, of which a negligible amount remains unchanged parent drug.
Volume of Distribution
The apparent volume of distribution at steady-state is 164 L.
Clearance
The mean apparent clearance of capmatinib at steady-state is 24 L/h.
Capmatinib undergoes metabolism primarily via CYP3A4 and aldehyde oxidase. Specific biotransformation pathways and metabolic products have yet to be elucidated.
The elimination half-life is 6.5 hours.
Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain - these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor - in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...
About the Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
ABOUT THIS PAGE
A Capmatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Capmatinib, including repackagers and relabelers. The FDA regulates Capmatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Capmatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Capmatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Capmatinib supplier is an individual or a company that provides Capmatinib active pharmaceutical ingredient (API) or Capmatinib finished formulations upon request. The Capmatinib suppliers may include Capmatinib API manufacturers, exporters, distributors and traders.
click here to find a list of Capmatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Capmatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Capmatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Capmatinib GMP manufacturer or Capmatinib GMP API supplier for your needs.
A Capmatinib CoA (Certificate of Analysis) is a formal document that attests to Capmatinib's compliance with Capmatinib specifications and serves as a tool for batch-level quality control.
Capmatinib CoA mostly includes findings from lab analyses of a specific batch. For each Capmatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Capmatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Capmatinib EP), Capmatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Capmatinib USP).
LOOKING FOR A SUPPLIER?